Drug Profile
Research programme: obesity therapy - Bayer/Lipomics Technologies
Alternative Names: obesity therapy research programme - Bayer/Lipomics TechnologiesLatest Information Update: 25 Mar 2010
Price :
$50
*
At a glance
- Originator Bayer; Lipomics Technologies
- Developer Lipomics Technologies
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 19 Jan 2004 Preclinical trials in Obesity in USA (unspecified route)